[1] European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 2012, 57: 167-185.
[2] Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int, 2012, 6: 531-561.
[3] Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology, 2009, 50: 661-662.
[4] European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol, 2009, 50: 227-242.
[5] 中华医学会肝病学分会,中华医学会感染病学分会。慢性乙型肝炎防治指南(2010年版). 中华肝脏病杂志, 2011, 19: 13-24.
[6] Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology, 2006, 44: 1656-1665.
[7] Li X, Chen Y, Ma Z, et al. Effect of regulatory T cells and adherent cells on the expansion of HBcAg-specific CD8+ T cells in patients with chronic hepatitis B virus infection. Cell Immunol, 2010, 264: 42-46.
[8] Stoop JN, van der Molen RG, Baan CC, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology, 2005, 41: 771-778. |
